This open-label, pilot study will evaluate the tolerance and change in the microbiome from the use of APR-TD011 ((RLF-TD011) wound cleansing spray for the treatment of CTCL skin lesions.

Inclusion Criteria:

• Adults with early-stage mycosis fungoides (stages IA-IB)
• At least two target lesions that have been present for at least 3 weeks and is at least 10 cm2 , so that at least one lesion may be allocated to each of the treatment regimes
• Target lesion with swab that is culture positive for staphylococcus aureus, but not to an extent that would require systemic antibiotics
• Agree to avoid washing or using a topical application at the target lesion starting the night before each scheduled study visit.
• Agree for the duration of study participation to avoid using dilute bleach or vinegar baths, or other antiseptic use, at the target lesion from screening throughout the study.

Exclusion Criteria:

• Patients currently or recently (within past 4 weeks) on topical or systemic antibiotics adults unable to provide informed consent, (infants, children, teenagers, pregnant women, prisoners and other vulnerable populations.